Nice presentation, and reassurance to shareholders that commercial deals on the table for US & China and elsewhere. Everything seems to be on track as planned. I presume considering size of US patient, the upfront revenue for US could be $20-25M (USD) for size of $60M market capital. Similar could be true for China, however China and US may take some time, possibly next year.
Keep believing, but patience is key here as Pharma trial takes time.
Ann: AGM Presentation, page-4
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $217.5M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 38.0¢ | $275.3K | 716.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 72085 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 38980 | 4 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |